Rigel CEO uses 2,424 shares for tax or exercise costs

RIGEL PHARMACEUTICALS’ CEO had shares returned to the issuer to cover option exercise price or tax obligations, reducing his holdings modestly.

Rhea-AI Filing Summary

RIGEL PHARMACEUTICALS INC (RIGL) reported that CEO and President Raul R. Rodriguez had 2,424 shares of common stock returned to the issuer on September 1, 2026 as a payment of exercise price or tax liability by delivering or withholding securities. The transaction price was $47.50 per share, and his directly held common stock position after this adjustment was 273,362 shares. A related footnote states that this reflects the return to the issuer of 3,807 shares previously reported as acquired under the issuer's employee stock purchase plan. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Exercise Price or Tax Liability: 2,424 shares

Exercise Price or Tax Liability 1 txn

Insider RODRIGUEZ RAUL R

Role CEO, President

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock F1	2,424	$47.50	$115K

Holdings After Transaction: Common Stock — 273,362 shares (Direct)

Footnotes (1)

1. F1. Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan.

Key Figures

Shares delivered or withheld: 2,424 shares Transaction price per share: $47.50 per share Shares held after transaction: 273,362 shares +2 more

5 metrics

Shares delivered or withheld 2,424 shares Common stock returned to issuer on September 1, 2026 to pay exercise price or tax liability

Transaction price per share $47.50 per share Valuation used for the 2,424-share payment of exercise price or tax liability

Shares held after transaction 273,362 shares CEO Raul R. Rodriguez’s directly held common stock following the September 1, 2026 adjustment

Footnote share reference 3,807 shares Shares returned to the issuer previously acquired under the employee stock purchase plan, per footnote

Exercise-price-or-tax-liability shares 2,424 shares Shares associated with payment of exercise price or tax liability in the filing’s transaction summary

Key Terms

Payment of exercise price or tax liability by delivering or withholding securities, Rule 10b5-1, employee stock purchase plan

3 terms

Payment of exercise price or tax liability by delivering or withholding securities financial

"reported as a payment of exercise price or tax liability by delivering or withholding"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

employee stock purchase plan financial

"previously reported as acquired under the Issuer's employee stock purchase plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RIGL report for CEO Raul R. Rodriguez on September 1, 2026?

RIGEL PHARMACEUTICALS reported that CEO Raul R. Rodriguez had 2,424 shares of common stock returned to the issuer on September 1, 2026 to pay exercise price or tax liability by delivering or withholding securities.

At what price were the 2,424 RIGL shares used for the CEO’s tax or exercise payment valued?

The 2,424 shares involved in the payment of exercise price or tax liability were valued at $47.50 per share, as reported for the September 1, 2026 transaction.

How many RIGL shares did the CEO hold after the September 1, 2026 transaction?

After the September 1, 2026 transaction, CEO Raul R. Rodriguez directly held 273,362 shares of RIGEL PHARMACEUTICALS common stock, according to the filing’s post-transaction holdings figure.

Was the September 1, 2026 RIGL insider transaction made under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirmed, and there is no footnote stating that the September 1, 2026 transaction was made under a Rule 10b5-1 trading plan.

What does the footnote about 3,807 RIGL shares indicate for this insider transaction?

A footnote states that the transaction reflects the return to the issuer of 3,807 shares previously reported as acquired under the issuer’s employee stock purchase plan, tying the adjustment to earlier ESPP-acquired shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 07:02 PM EDT Accepted by SEC EDGAR 09/03/2026 - 06:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RODRIGUEZ RAUL R

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		F		2,424	D	$47.5	273,362(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan.

	/s/ Raymond Furey (Attorney-in-Fact)	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)